RRC ID 44528
著者 Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A.
タイトル Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
ジャーナル Cancer Lett
Abstract RET gene fusions are recurrent oncogenes identified in thyroid and lung carcinomas. Lenvatinib is a multi-tyrosine kinase inhibitor currently under evaluation in several clinical trials. Here we evaluated lenvatinib in RET gene fusion-driven preclinical models. In cellular assays, lenvatinib inhibited auto-phosphorylation of KIF5B-RET, CCDC6-RET, and NcoA4-RET. Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells. These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.
巻・号 340(1)
ページ 97-103
公開日 2013-10-28
DOI 10.1016/j.canlet.2013.07.007
PII S0304-3835(13)00512-0
PMID 23856031
MeSH Animals Antineoplastic Agents / pharmacology* Cell Line, Tumor Cell Transformation, Neoplastic / drug effects Cell Transformation, Neoplastic / genetics Cytoskeletal Proteins / genetics Cytoskeletal Proteins / metabolism Drug Screening Assays, Antitumor Female Humans Mice Mice, Inbred BALB C Mice, Nude NIH 3T3 Cells Neoplasm Transplantation Neoplasms / drug therapy* Neoplasms / enzymology Neoplasms / genetics Oncogene Proteins, Fusion / antagonists & inhibitors* Oncogene Proteins, Fusion / genetics Oncogene Proteins, Fusion / metabolism Phenylurea Compounds / pharmacology* Protein Kinase Inhibitors / pharmacology Proto-Oncogene Proteins c-ret / antagonists & inhibitors* Proto-Oncogene Proteins c-ret / genetics Proto-Oncogene Proteins c-ret / metabolism Quinolines / pharmacology* Signal Transduction
IF 7.36
引用数 126
WOS 分野 ONCOLOGY
リソース情報
ヒト・動物細胞 LC-2/ad(RCB0440)